Tuesday, October 14, 2014 1:27:08 PM
10 drugs that could stop Ebola
October 14, 2014 | By Emily Mullin
Before the current Ebola outbreak, the virus had only appeared in Africa in fits and starts since its discovery in 1976, receding back into the jungle almost as quickly as it arrived. This relative rarity and the swiftness with which the disease kills its victims has, up until now, made Ebola an unattractive--not to mention daunting--prospect for drug developers. As a result, no approved drugs or vaccines against Ebola exist.
As the current situation in West Africa worsens, more people have died from Ebola since the current outbreak began in December 2013 than in all previous outbreaks combined. The public health crisis has prompted the World Health Organization to call on international government agencies and the pharmaceutical industry to work together to speed up the development of promising therapies for experimental use for those most at risk of contracting the disease, which causes severe hemorrhagic fever.
Now, a handful of players are racing to get a treatment or vaccine to patients as quickly as possible, even though these drugs remain largely untested in humans. We've compiled a list of organizations that are in the global spotlight right now with their investigational Ebola programs. -- Emily Mullin
Bavarian Nordic/Johnson & Johnson
Name: MVA-BN filo/AdVac (vaccine)
Phase: Preclinical (Phase I trials to begin in 2015)
The scoop: Prime-boost regimen that combines Bavarian Nordic's MVA-BN platform (cancer vaccine consisting of an attenuated version of the modified vaccinia ankara virus encoding a filovirus antigen) with
J&J's AdVac vector system
BioCryst Pharmaceuticals
Name: BCX4430
Phase: Preclinical
The scoop: RNA-dependent RNA polymerase inhibitor
Chimerix
Name: Brincidofovir
Phase: II/III (exploratory)
The scoop: Oral nucleotide analog
GlaxoSmithKline/National Institute of Allergy and Infectious Diseases
Name: cAd3-ZEBOV (vaccine)
Phase: I
The scoop: Uses an attenuated strain of chimpanzee cold virus, called chimp adenovirus type 3 (ChAd3), as a vector to deliver benign genetic material derived from the Ebola Zaire virus strain
Inovio Pharmaceuticals
Name: SynCon (vaccine)
Phase: Preclinical
The scoop: Polyvalent DNA vaccine containing three consensus plasmids to broadly target variant virus strains within three distinct families of Ebola and Marburg viruses
Mapp Biopharmaceutical
Name: ZMapp
Phase: Preclinical
The scoop: Mixture of three "humanized" monoclonal antibodies manufactured in plants, specifically Nicotiana
NewLink Genetics/Public Health Agency of Canada
Name: rVSV-ZEBOV (vaccine)
Phase: I
The scoop: Based on attenuated strains of vesicular stomatitis virus, a common animal virus, modified to express an ebolavirus protein that is nonpathologic in primates and mice
Profectus BioSciences
Name: VesiculoVax (vaccine)
Phase: Preclinical
The scoop: Recombinant vesicular stomatitis virus (rVSV) expressing surface glycoproteins from ebolavirus
Sarepta Therapeutics
Name: AVI-7537
Phase: I
The scoop: Binds to viral RNA and inhibits the synthesis of the nucleocapsid protein, which supports the replication of the viral genetic material in an infected cell
Tekmira
Name: TKM-Ebola (Ebola SNALP)
Phase: I
The scoop: Contains three small interfering RNA molecules packaged into the company's proprietary lipid nanoparticle technology
http://www.fiercebiotechresearch.com/story/10-drugs-could-stop-ebola/2014-10-14?utm_medium=nl&utm_source=internal
All I say is IMHO and not to be construed as investment advice. I know nothing, as informed frequently by my wife.
Recent INO News
- INOVIO to Present at Upcoming Scientific Conference • PR Newswire (US) • 09/17/2024 08:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/13/2024 10:22:02 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 10:06:54 AM
- INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights • PR Newswire (US) • 08/08/2024 08:05:00 PM
- INOVIO Reports Inducement Grant Under Inducement Plan • PR Newswire (US) • 08/01/2024 08:05:00 PM
- Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107 • PR Newswire (US) • 07/25/2024 08:05:00 PM
- INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024 • PR Newswire (US) • 07/25/2024 12:00:00 PM
- INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway • PR Newswire (US) • 07/11/2024 12:00:00 PM
- INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer • PR Newswire (US) • 07/02/2024 08:05:00 PM
- INOVIO Reports Inducement Grant Under Inducement Plan • PR Newswire (US) • 07/01/2024 08:00:00 PM
- INOVIO Added to Russell 2000® Index Effective July 1, 2024 • PR Newswire (US) • 07/01/2024 12:00:00 PM
- INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc. • PR Newswire (US) • 06/04/2024 12:00:00 PM
- INOVIO Reports Inducement Grants Under Inducement Plan • PR Newswire (US) • 05/31/2024 08:48:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 08:01:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:50:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:50:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:49:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:13:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:12:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:11:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:10:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM